P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells

Nanomedicine

Volumn 7, Issue 1, 2012, Pages 65-78

  Navarro, Gemma ^a   Sawant, Rupa R ^a   Biswas, Swati ^a   Essex, Sean ^a   Tros De Ilarduya, Conchita ^b   Torchilin, Vladimir P ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

MCF 7 breast cancer cell; micelle like nanoparticle; multidrug resistance; P glycoprotein; polyethylenimine; siRNA delivery

Indexed keywords

DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DOXORUBICIN; GLYCOPROTEIN P; LIPID; MACROGOL; NANOPARTICLE; POLYETHYLENEIMINE; SMALL INTERFERING RNA;

ARTICLE; BIOCOMPATIBILITY; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MICELLE; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE SILENCING; HUMANS; NANOCONJUGATES; P-GLYCOPROTEIN; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENEIMINE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84555202691     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.93     Document Type: Article

References (45)

1. Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer. Methods Mol. Biol. 596, 47-76 (2010).
2. Constantinides PP, Wasan KM. Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies. J. Pharm. Sci. 96, 235-248 (2007). (Pubitemid 46363554)
3. Staud F, Ceckova M, Micuda S, Pavek P. Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics. Methods Mol. Biol. 596, 199-222 (2010).
4. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75, 13-33 (2004). (Pubitemid 38130115)
5. Chen H, Hao J, Wang L, Li Y. Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br. J. Cancer 101, 432-440 (2009).
6. Lee TB, Park JH, Min YD, Kim KJ, Choi CH. Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy. BMC Gastroenterol. 8, 33 (2008).
7. Mahadevan D, List AF. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood 104, 1940-1951 (2004). (Pubitemid 39297842)
8. Keshet GI, Goldstein I, Itzhaki O et al. MDR1 expression identifes human melanoma stem cells. Biochem. Biophys. Res. Commun. 368, 930-936 (2008).
9. Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr. Relat. Cancer 10, 43-73 (2003). (Pubitemid 36457239)
10. Mechetner E, Kyshtoobayeva A, Zonis S et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin. Cancer Res. 4, 389-398 (1998). (Pubitemid 28122754)
11. Colabufo NA, Berardi F, Cantore M et al. Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials. J. Med. Chem. 53, 1883-1897 (2010).
12. Dantzig AH, de Alwis DP, Burgess M. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv. Drug Deliv. Rev. 55, 133-150 (2003). (Pubitemid 36078455)
13. Lage H. MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. Curr. Drug Targets 7, 813-821 (2006).
14. Stege A, Kruhn A, Lage H. Overcoming multidrug resistance by RNA interference. Methods Mol. Biol. 596, 447-465 (2010).
15. Elbashir SM, Harborth J, Lendeckel W et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498 (2001). (Pubitemid 32494397)
16. Grayson AC, Doody AM, Putnam D. Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm. Res. 23, 1868-1876 (2006). (Pubitemid 44200551)
17. Hobel S, Aigner A. Polyethylenimine (PEI)/siRNA-mediated gene knockdown in vitro and in vivo. Methods Mol. Biol. 623, 283-297 (2010).
18. Neu M, Fischer D, Kissel T Recent advances in rational gene transfer vector design based on poly(ethylene imine) and its derivatives. J. Gene Med. 7, 992-1009 (2005). (Pubitemid 41195062)
19. Ogris M, Steinlein P, Carotta S, Brunner S, Wagner E. DNA/polyethylenimine transfection particles: infuence of ligands, polymer size, and PEGylation on internalization and gene expression. AAPS PharmSci. 3, E21 (2001).
20. Boussif O, Lezoualc h F, Zanta MA et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl Acad. Sci. USA 92, 7297-7301 (1995).
21. Alshamsan A, Haddadi A, Incani V et al. Formulation and delivery of siRNA by oleic acid and stearic acid modifed polyethylenimine. Mol. Pharm. 6, 121-133 (2009).
22. Liu C, Zhao G, Liu J et al. Novel biodegradable lipid nano complex for siRNA delivery signifcantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel. J. Control. Release 140, 277-283 (2009).
23. Gusachenko O, Kravchuk Y, Konevets D et al. Transfection effciency of 25-kDa PEI-cholesterol conjugates with different levels of modifcation. J. Biomater. Sci. Polym. Ed. 20, 1091-1110 (2009).
24. Han S, Mahato RI, Kim SW. Water-soluble lipopolymer for gene delivery. Bioconjug. Chem. 12, 337-345 (2001). (Pubitemid 32464179)
25. Abbasi M, Lavasanifar A, Berthiaume LG, Weinfeld M, Uludag H. Cationic polymer-mediated small interfering RNA delivery for P-glycoprotein downregulation in tumor cells. Cancer 116, 5544-5554 (2010).
26. Rothdiener M, Muller D, Castro PG et al. Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems. J. Control. Release 144, 251-258 (2010).
27. Schafer J, Hobel S, Bakowsky U, Aigner A. Liposome-polyethylenimine complexes for enhanced DNA and siRNA delivery. Biomaterials 31, 6892-6900 (2010).
28. Ko YT, Kale A, Hartner WC, Papahadjopoulos-Sternberg B, Torchilin VP. Self-assembling micelle-like nanoparticles based on phospholipid- polyethyleneimine conjugates for systemic gene delivery. J. Control. Release 133, 132-138 (2009).
29. Navarro G, Sawant R, Essex S, Tros de ILarduya C, Torchilin V P. Phospholipid-polyethylenimine conjugate-based micelle-like nanoparticles for siRNA delivery. Drug Deliv. Transl. Res. 1, 25-33 (2010).
30. Musacchio T, Vaze O, D'Souza G, Torchilin V P. Effective stabilization and delivery of siRNA: reversible siRNA-phospholipid conjugate in nanosized mixed polymeric micelles. Bioconjug. Chem. 21, 1530-1536 (2010).
31. Wu H, Hait WN, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 63, 1515-1519 (2003). (Pubitemid 36373637)
32. Saad M, Garbuzenko OB, Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond.) 3, 761-776 (2008).
33. Mao S, Neu M, Germershaus O et al. Infuence of polyethylene glycol chain length on the physicochemical and biological properties of poly(ethylene imine)-graft-poly(ethylene glycol) block copolymer/SiRNA polyplexes. Bioconjug. Chem. 17, 1209-1218 (2006). (Pubitemid 44455329)
34. Malek A, Czubayko F, Aigner A. PEG grafting of polyethylenimine (PEI) exerts different effects on DNA transfection and siRNA-induced gene targeting effcacy. J. Drug Target 16, 124-139 (2008). (Pubitemid 351266549)
35. Kabanov AV, Kabanov VA. DNA complexes with polycations for the delivery of genetic material into cells. Bioconjug. Chem. 6, 7-20 (1995).
36. Grayson, AC, Doody AM, Putnam D. Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm. Res. 23, 1868-1876 (2006). (Pubitemid 44200551)
37. Peng Z, Xiao Z, Wang Y et al. Reversal of P-glycoprotein-mediated multidrug resistance with small interference RNA (siRNA) in leukemia cells. Cancer Gene Ther. 11, 707-712 (2004). (Pubitemid 39488468)
38. Yadav S, van Vlerken LE, Little SR, Amiji MM. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother. Pharmacol. 63, 711-722 (2009).
39. Germano S, O'Driscoll L. Breast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine. Curr. Cancer Drug Targets 9, 398-418 (2009).
40. Jiang J, Yang SJ, Wang JC et al. Sequential treatment of drug-resistant tumors with RGD-modifed liposomes containing siRNA or doxorubicin. Eur. J. Pharm. Biopharm. 76, 170-178 (2010).
41. Patil YB, Swaminathan SK, Sadhukha T, Ma L, Panyam J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 31, 358-365 (2009).
42. Sun TM, Du JZ, Yao YD et al. Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression. ACS Nano. 5, 1483-1494 (2011).
43. Philipp A, Zhao X, Tarcha P, Wagner E, Zintchenko A. Hydrophobically modifed oligoethylenimines as highly effcient transfection agents for siRNA delivery Bioconjug Chem. 20, 2055-2061 (2009).
44. Yamazaki Y, Nango M, Matsuura M et al. Polycation liposomes, a novel nonviral gene transfer system, constructed from cetylated polyethylenimine. Gene Ther. 7, 1148-1155 (2000). (Pubitemid 30458807)
45. Chen JL, Wang H, Gao JQ, Chen HL, Liang WQ. Liposomes modifed with polycation used for gene delivery: preparation, characterization and transfection in vitro. Int. J. Pharm. 343, 255-261 (2007). (Pubitemid 47321024)